WeVote
Log In

Bill

Bill

S 4692

Homeopathic Drug Product Safety, Quality, and Transparency Act

119th Congress Introduced by Mike Lee and 1 co-sponsor

Creates a separate regulatory track for homeopathic drug products with dedicated GMP, labeling, testing, and an advisory committee under the FD&C Act.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 4692

Summary of Bill: Homeopathic Drug Product Safety, Quality, and Transparency Act (S.4692, 119th Congress)

Purpose and intent

  • Establishes a distinct regulatory framework for homeopathic drug products within the Federal Food, Drug, and Cosmetic Act (FD&C Act).
  • Aims to provide a clear, statutory basis for safety, quality, and labeling of homeopathic drug products, recognizing their historical use and unique preparation methods.
  • Replaces reliance on existing non-premarket approaches with a formal set of standards and a dedicated advisory mechanism.

Key provisions and changes

  • Definitions and scope

    • Adds “homeopathic drug product” to the list of regulated drug categories.
    • Defines a homeopathic drug product as containing one or more homeopathic ingredients and no other active ingredient.
    • Defines a “homeopathic ingredient” as either listed in the Homeopathic Pharmacopoeia of the United States (HPUS) or prepared under recognized homeopathic manufacturing methods and safety/quality standards (HPUS or other recognized pharmacopoeias).

  • Regulation and oversight

    • Creates a separate regulatory track for homeopathic drug products under the FD&C Act, limited to specific sections (primarily sections 501, 502, and 510). It would not require premarket approval under section 505.
    • The Secretary of Health and Human Services would regulate homeopathic products using standards appropriate to their characteristics and recognized by the Secretary, in alignment with HPUS and other recognized standards.

  • Good Manufacturing Practices (GMP) and labeling

    • Requires the Secretary to issue a final rule within 3 years establishing current Good Manufacturing Practices (cGMP) and labeling requirements specifically for homeopathic drug products.
    • Standards must be appropriate, not conflict with HPUS-derived standards, and not rely on analytical methods unavailable for these products.

  • Product testing and safety

    • Final product testing: Finished homeopathic products must meet final specs (e.g., contaminants, defects) but are exempt from identity/strength testing of individual active ingredients found in conventional drugs.
    • Intermediate testing for starting materials: If a starting material could pose substantial risk in undiluted form, manufacturers must ensure and document that the substance in intermediate attenuations remains below a safe level, as defined by HPUS standards or other nationally recognized safety standards, or below analytically detectable levels.

  • Labeling, intended use, and claims

    • Labels must comply with general labeling rules, but dosage units may reflect homeopathic attenuations.
    • Intended uses for retail homeopathic products must describe self-limiting conditions and include a cautionary disclaimer that FDA has not evaluated these uses.
    • Non-retail (special) homeopathic products may omit certain intended-use statements.
    • Claims must be supported by evidence appropriate to the product’s risk profile, including traditional homeopathic principles and real-world evidence; claims for specific conditions must start with “Traditionally used for.”

  • Advertising and misbranding

    • If a product’s labeling bears terms like “homeopathic” but is not a true homeopathic product, it could be treated as misbranded under the FD&C Act.

  • Homeopathic Drug Product Advisory Committee

    • Establishes a government advisory committee to provide guidance on safety, quality, labeling, and regulatory approaches.
    • Committee membership should reflect diverse perspectives from practitioners, manufacturers of various sizes, educators, and consumer representatives.
    • Committee recommendations can influence guidance, rulemaking, GMP standards, and enforcement initiatives; however, the Secretary is not bound to follow every recommendation.
    • The committee would terminate seven years after its establishment.

  • Administrative and conforming amendments

    • Aligns related provisions in other statutes (e.g., distribution chains, adverse event reporting, biosafety exemptions) to reference homeopathic products within the new framework.
    • Adds and clarifies reporting and labeling provisions related to adverse events and postmarket surveillance.

  • Withdrawal of prior guidance

    • Repeals FDA guidance titled “Homeopathic Drug Products; Guidance for FDA Staff and Industry,” removing that guidance from force.

Who is affected

  • Homeopathic drug product manufacturers and distributors.
  • Practitioners and consumers of homeopathic products.
  • Regulated entities will interact with a dedicated regulatory framework rather than traditional premarket drug approval pathways.
  • The Homeopathic Drug Product Advisory Committee, with diverse stakeholder representation.

Procedural and timeline notes

  • Final GMP and labeling rule: to be issued no later than three years after enactment.
  • The Advisory Committee has a seven-year term from establishment.
  • Guidance withdrawn: the FDA’s 2022 homeopathic guidance would be nullified.

Note: This summary reflects the bill’s explicit provisions and does not project enactment effects beyond the text.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.